JP2017533912A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533912A5 JP2017533912A5 JP2017523273A JP2017523273A JP2017533912A5 JP 2017533912 A5 JP2017533912 A5 JP 2017533912A5 JP 2017523273 A JP2017523273 A JP 2017523273A JP 2017523273 A JP2017523273 A JP 2017523273A JP 2017533912 A5 JP2017533912 A5 JP 2017533912A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- cancer
- administered
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 35
- 229960003301 nivolumab Drugs 0.000 claims 13
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 12
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 12
- 201000002528 pancreatic cancer Diseases 0.000 claims 12
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 12
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 11
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 11
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 11
- 206010009944 Colon cancer Diseases 0.000 claims 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 9
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 9
- 206010005003 Bladder cancer Diseases 0.000 claims 6
- 206010014733 Endometrial cancer Diseases 0.000 claims 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 6
- 206010018338 Glioma Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 206010033128 Ovarian cancer Diseases 0.000 claims 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 6
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 6
- 208000029824 high grade glioma Diseases 0.000 claims 6
- 201000011614 malignant glioma Diseases 0.000 claims 6
- 201000001441 melanoma Diseases 0.000 claims 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims 6
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 5
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 3
- 238000012447 xenograft mouse model Methods 0.000 claims 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 2
- 238000009175 antibody therapy Methods 0.000 claims 2
- 102000052833 human CSF1R Human genes 0.000 claims 2
- 102000048362 human PDCD1 Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 238000003782 apoptosis assay Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 102200006539 rs121913529 Human genes 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462072035P | 2014-10-29 | 2014-10-29 | |
| US62/072,035 | 2014-10-29 | ||
| US201562157368P | 2015-05-05 | 2015-05-05 | |
| US62/157,368 | 2015-05-05 | ||
| US201562192025P | 2015-07-13 | 2015-07-13 | |
| US62/192,025 | 2015-07-13 | ||
| PCT/US2015/057781 WO2016069727A1 (en) | 2014-10-29 | 2015-10-28 | Combination therapy for cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020121946A Division JP2020186243A (ja) | 2014-10-29 | 2020-07-16 | がんのための併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533912A JP2017533912A (ja) | 2017-11-16 |
| JP2017533912A5 true JP2017533912A5 (2) | 2018-12-06 |
| JP6920989B2 JP6920989B2 (ja) | 2021-08-18 |
Family
ID=54695820
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523273A Active JP6920989B2 (ja) | 2014-10-29 | 2015-10-28 | がんのための併用療法 |
| JP2020121946A Pending JP2020186243A (ja) | 2014-10-29 | 2020-07-16 | がんのための併用療法 |
| JP2022207154A Pending JP2023052067A (ja) | 2014-10-29 | 2022-12-23 | がんのための併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020121946A Pending JP2020186243A (ja) | 2014-10-29 | 2020-07-16 | がんのための併用療法 |
| JP2022207154A Pending JP2023052067A (ja) | 2014-10-29 | 2022-12-23 | がんのための併用療法 |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US9765147B2 (2) |
| EP (2) | EP3212670B1 (2) |
| JP (3) | JP6920989B2 (2) |
| KR (1) | KR102636539B1 (2) |
| CN (1) | CN107567336B (2) |
| AU (1) | AU2015339306B2 (2) |
| BR (1) | BR112017008914A2 (2) |
| CA (1) | CA2963147A1 (2) |
| CY (1) | CY1123957T1 (2) |
| DK (1) | DK3212670T3 (2) |
| EA (1) | EA036261B1 (2) |
| ES (1) | ES2851390T3 (2) |
| HR (1) | HRP20210440T1 (2) |
| HU (1) | HUE054012T2 (2) |
| IL (1) | IL251464B2 (2) |
| LT (1) | LT3212670T (2) |
| MX (1) | MX381046B (2) |
| PL (1) | PL3212670T3 (2) |
| PT (1) | PT3212670T (2) |
| RS (1) | RS61602B1 (2) |
| SG (1) | SG11201702723VA (2) |
| SI (1) | SI3212670T1 (2) |
| SM (1) | SMT202100164T1 (2) |
| TW (1) | TWI711463B (2) |
| WO (1) | WO2016069727A1 (2) |
| ZA (1) | ZA201702382B (2) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130302322A1 (en) * | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| HK1203971A1 (en) * | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| HUE045065T2 (hu) | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| PL3102605T3 (pl) | 2014-02-04 | 2019-06-28 | Pfizer Inc. | Połączenie antagonisty pd-1 i inhibitora vegfr do leczenia nowotworu |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| SG11201610672YA (en) * | 2014-06-23 | 2017-01-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| EP3212670B1 (en) | 2014-10-29 | 2020-12-23 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| BR112017011536A2 (pt) * | 2014-12-02 | 2018-02-27 | Celgene Corp | terapias de combinação |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| RU2714233C2 (ru) | 2015-02-26 | 2020-02-13 | Мерк Патент Гмбх | Ингибиторы pd-1 / pd-l1 для лечения рака |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| AU2016249981B2 (en) | 2015-04-13 | 2022-02-17 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| JP2018514550A (ja) | 2015-04-28 | 2018-06-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| JP6851322B2 (ja) * | 2015-05-27 | 2021-03-31 | ユーシービー バイオファルマ エスアールエル | 神経疾患を治療する方法 |
| MY193229A (en) | 2015-06-16 | 2022-09-26 | Merck Patent GmbH | Pd-l1 antagonist combination treatments |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| HRP20211058T8 (hr) | 2015-07-29 | 2021-11-26 | Novartis Ag | Kombinirane terapije koje sadrže molekule antitijela protiv lag-3 |
| IL260021B (en) | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| CN109475634A (zh) * | 2016-06-03 | 2019-03-15 | 百时美施贵宝公司 | 用于治疗复发性小细胞肺癌的方法的抗-pd-1抗体 |
| AU2017306506B2 (en) * | 2016-08-05 | 2020-05-21 | Y-Biologics Inc. | Antibody to programmed cell death 1 (PD-1) and use thereof |
| CN109790220A (zh) | 2016-08-25 | 2019-05-21 | 豪夫迈·罗氏有限公司 | 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药 |
| EP4026849A1 (en) * | 2016-09-26 | 2022-07-13 | Ensemble Group Holdings | Methods of assessing and treating cancer in subjects having dysregulated lymphatic systems using a combination of vegfr-3 and pd-1 or pd-l1 inhibitors |
| KR20190062515A (ko) | 2016-10-06 | 2019-06-05 | 화이자 인코포레이티드 | 암의 치료를 위한 아벨루맙의 투약 용법 |
| WO2018093591A1 (en) | 2016-11-03 | 2018-05-24 | Juno Therapeutics, Inc. | Combination therapy of a cell based therapy and a microglia inhibitor |
| CN110072553B (zh) | 2016-12-22 | 2023-09-15 | 豪夫迈·罗氏有限公司 | 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗 |
| ES2863412T3 (es) * | 2017-03-29 | 2021-10-11 | Shionogi & Co | Composición farmacéutica para el tratamiento del cáncer |
| CN110709422B (zh) | 2017-04-19 | 2023-12-26 | 马伦戈治疗公司 | 多特异性分子及其用途 |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| EP3681535A1 (en) | 2017-09-13 | 2020-07-22 | Five Prime Therapeutics, Inc. | Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer |
| CN111655288A (zh) * | 2017-11-16 | 2020-09-11 | 诺华股份有限公司 | 组合疗法 |
| WO2019110662A1 (en) * | 2017-12-05 | 2019-06-13 | Progastrine Et Cancers S.À R.L. | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer |
| EP3720881A1 (en) * | 2017-12-08 | 2020-10-14 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| WO2019139583A1 (en) * | 2018-01-10 | 2019-07-18 | Lee Patrice A | Methods and combination therapy to treat cancer |
| US11692029B2 (en) * | 2018-03-05 | 2023-07-04 | The Schepens Eye Research Institute, Inc. | Therapy for glaucoma and optic neuropathy by targeting colony stimulating factors |
| CN108610422B (zh) * | 2018-03-29 | 2019-05-28 | 中国人民解放军军事科学院军事医学研究院 | 抑制pd-1/pd-l1信号通路的结合分子 |
| KR20200139724A (ko) * | 2018-03-30 | 2020-12-14 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| WO2020027217A1 (ja) * | 2018-07-31 | 2020-02-06 | 国立大学法人北海道大学 | がんの治療及び／又は予防のための医薬 |
| EP3853251A1 (en) * | 2018-09-19 | 2021-07-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy |
| WO2020227431A1 (en) | 2019-05-06 | 2020-11-12 | Brown University | Bispecific antibodies against chi3l1 and pd1 with enhanced t cell-mediated cytotoxic effects on tumor cells |
| CN114126648A (zh) * | 2019-05-31 | 2022-03-01 | Alx肿瘤生物技术公司 | 用SIRPα Fc融合体组合免疫检查点抑制剂治疗癌症的方法 |
| BR112022002028A2 (pt) * | 2019-08-02 | 2022-04-12 | Cttq Akeso Shanghai Biomed Tech Co Ltd | Anticorpo anti-pd-1 e uso farmacêutico do mesmo |
| CN121243368A (zh) | 2019-11-27 | 2026-01-02 | Alx肿瘤生物技术公司 | 用于治疗癌症的组合疗法 |
| CN114907267A (zh) * | 2021-02-08 | 2022-08-16 | 中国科学院上海药物研究所 | 用于抗肿瘤的药物组合 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| WO2025129066A1 (en) * | 2023-12-15 | 2025-06-19 | The Regents Of The University Of California | Detection, prevention, and reversal of acquired resistance to immune checkpoint blockade therapy |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0382781B1 (en) | 1987-10-23 | 1993-09-29 | Genetics Institute, Inc. | Composition for treating cancers characterized by over-expression of the c-fms proto-oncogene |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0668914B1 (en) | 1992-06-09 | 2000-08-16 | Chiron Corporation | Crystallization of m-csf |
| US20020193575A1 (en) | 1993-09-07 | 2002-12-19 | Smithkline Beecham P.L.C. | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| WO1999029345A1 (en) | 1997-12-05 | 1999-06-17 | La Jolla Institute For Experimental Medicine | Inhibition of tumor growth by macrophage intervention |
| CA2348292A1 (en) | 1998-10-30 | 2000-05-11 | Takeda Chemical Industries, Ltd. | Betacellulin protein-containing preparation |
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| WO2001030381A2 (de) | 1999-10-28 | 2001-05-03 | Hofbauer, Reinhold | Verwendung von csf-1-inhibitoren |
| WO2001034177A2 (en) | 1999-11-08 | 2001-05-17 | The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health | Method of treating a viral infection using antagonists of macrophage colony stimulating factor |
| US7108852B2 (en) | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| US7455836B2 (en) | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
| US6773895B2 (en) | 2000-09-01 | 2004-08-10 | Boehringer Ingelheim Pharma Kg | Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases |
| US7247618B2 (en) | 2001-04-30 | 2007-07-24 | Tripathi Rajavashisth | Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling |
| CA2450793A1 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| DE60332483D1 (de) | 2002-11-15 | 2010-06-17 | Novartis Vaccines & Diagnostic | Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7807389B2 (en) | 2003-03-14 | 2010-10-05 | University Of Rochester | Methods and compositions related to joint inflammation diseases |
| DK1638941T3 (da) | 2003-05-22 | 2010-10-11 | Abbott Lab | Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer |
| CA2541651C (en) | 2003-10-22 | 2011-05-24 | Keck Graduate Institute | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
| GB0325836D0 (en) | 2003-11-05 | 2003-12-10 | Celltech R&D Ltd | Biological products |
| JP2007524671A (ja) | 2004-01-21 | 2007-08-30 | カイロン コーポレイション | Ｍ−ｃｓｆムテインおよびその使用 |
| CA2565974A1 (en) | 2004-05-14 | 2005-12-01 | Receptor Biologix, Inc. | Cell surface receptor isoforms and methods of identifying and using the same |
| EP2479277B1 (en) | 2004-07-22 | 2015-09-02 | Five Prime Therapeutics, Inc. | Use of MGD-CSF in a method of treatment of Alzheimer's disease. |
| WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
| CA2589895A1 (en) | 2005-01-27 | 2006-08-03 | Five Prime Therapeutics, Inc. | Leader sequences for directing secretion of polypeptides and methods for production thereof |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| EP1945662A2 (en) | 2005-11-10 | 2008-07-23 | Receptor Biologix, Inc. | Methods for production of receptor and ligand isoforms |
| WO2007075933A2 (en) | 2005-12-21 | 2007-07-05 | Cell Signaling Technology, Inc. | Translocation and mutant csf1r kinase in human leukemia |
| CN101379400A (zh) | 2005-12-22 | 2009-03-04 | 诺华有限公司 | 可溶性人m-csf受体及其应用 |
| CN101534858A (zh) | 2006-01-05 | 2009-09-16 | 诺华有限公司 | 预防和治疗癌症转移和癌症转移相关性骨丢失的方法 |
| JP2010510219A (ja) | 2006-11-17 | 2010-04-02 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | アミロイド関連障害を処置するためのコロニー刺激因子の全身投与 |
| US7919594B2 (en) | 2007-02-14 | 2011-04-05 | Vaccinex, Inc. | Human anti-CD100 antibodies |
| WO2008124858A2 (en) | 2007-04-11 | 2008-10-23 | F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. | Targeted receptor |
| WO2008150383A1 (en) | 2007-05-30 | 2008-12-11 | Albert Einstein College Of Medicine Of Yeshiva University | Csf-1r mutants |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| PL2188313T3 (pl) | 2007-08-21 | 2018-04-30 | Amgen, Inc. | Białka wiążące ludzki antygen c-fms |
| US7981415B2 (en) | 2007-09-07 | 2011-07-19 | Cisthera, Inc. | Humanized PAI-1 antibodies |
| WO2009058968A2 (en) | 2007-10-31 | 2009-05-07 | Janssen Pharmaceutica N.V. | Biomarker for assessing response to fms treatment |
| EP2241333A1 (en) | 2007-12-12 | 2010-10-20 | National Cancer Center | Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| BRPI0909044B8 (pt) | 2008-03-14 | 2021-05-25 | Transgene Sa | anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos |
| US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| US20110129456A1 (en) * | 2008-05-05 | 2011-06-02 | Yaolin Wang | Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer |
| WO2010001617A1 (en) * | 2008-07-04 | 2010-01-07 | Ono Pharmaceutical Co., Ltd. | Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| WO2010062399A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Csf1r extracellular domain fusion molecules and treatments using same |
| US8183207B2 (en) | 2008-11-26 | 2012-05-22 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| AR080698A1 (es) | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| HRP20190047T1 (hr) * | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| CN107090029B (zh) * | 2010-11-11 | 2021-07-13 | 港大科桥有限公司 | 可溶性 pd-1变体、融合构建体及其用途 |
| TW201307845A (zh) | 2010-12-13 | 2013-02-16 | Novartis Ag | 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法 |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| WO2013057281A2 (en) | 2011-10-21 | 2013-04-25 | Transgene Sa | Modulation of macrophage activation |
| US20140288279A1 (en) | 2011-10-21 | 2014-09-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | M-DC8+ Monocyte Depleting Agent for the Prevention or the Treatment of a Condition Associated with a Chronic Hyperactivation of the Immune System |
| AR090263A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| EP3212670B1 (en) | 2014-10-29 | 2020-12-23 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| MA40737A (fr) | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| CA3038712A1 (en) | 2016-10-06 | 2018-04-12 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| JP7760242B2 (ja) | 2017-07-21 | 2025-10-27 | ジェネンテック， インコーポレイテッド | がんの治療法及び診断法 |
-
2015
- 2015-10-28 EP EP15798264.6A patent/EP3212670B1/en active Active
- 2015-10-28 MX MX2017005553A patent/MX381046B/es unknown
- 2015-10-28 LT LTEP15798264.6T patent/LT3212670T/lt unknown
- 2015-10-28 JP JP2017523273A patent/JP6920989B2/ja active Active
- 2015-10-28 HR HRP20210440TT patent/HRP20210440T1/hr unknown
- 2015-10-28 SM SM20210164T patent/SMT202100164T1/it unknown
- 2015-10-28 US US14/925,534 patent/US9765147B2/en active Active
- 2015-10-28 IL IL251464A patent/IL251464B2/en unknown
- 2015-10-28 KR KR1020177014031A patent/KR102636539B1/ko active Active
- 2015-10-28 SG SG11201702723VA patent/SG11201702723VA/en unknown
- 2015-10-28 CA CA2963147A patent/CA2963147A1/en active Pending
- 2015-10-28 WO PCT/US2015/057781 patent/WO2016069727A1/en not_active Ceased
- 2015-10-28 EP EP20207287.2A patent/EP3835323A1/en not_active Withdrawn
- 2015-10-28 CN CN201580071491.1A patent/CN107567336B/zh active Active
- 2015-10-28 RS RS20210347A patent/RS61602B1/sr unknown
- 2015-10-28 SI SI201531496T patent/SI3212670T1/sl unknown
- 2015-10-28 PT PT157982646T patent/PT3212670T/pt unknown
- 2015-10-28 TW TW104135474A patent/TWI711463B/zh not_active IP Right Cessation
- 2015-10-28 DK DK15798264.6T patent/DK3212670T3/da active
- 2015-10-28 ES ES15798264T patent/ES2851390T3/es active Active
- 2015-10-28 EA EA201790926A patent/EA036261B1/ru not_active IP Right Cessation
- 2015-10-28 HU HUE15798264A patent/HUE054012T2/hu unknown
- 2015-10-28 AU AU2015339306A patent/AU2015339306B2/en not_active Ceased
- 2015-10-28 BR BR112017008914A patent/BR112017008914A2/pt not_active Application Discontinuation
- 2015-10-28 PL PL15798264T patent/PL3212670T3/pl unknown
-
2017
- 2017-04-04 ZA ZA2017/02382A patent/ZA201702382B/en unknown
- 2017-08-18 US US15/680,664 patent/US10221244B2/en active Active
-
2019
- 2019-01-09 US US16/243,510 patent/US10618967B2/en active Active
-
2020
- 2020-03-04 US US16/808,910 patent/US11566076B2/en active Active
- 2020-07-16 JP JP2020121946A patent/JP2020186243A/ja active Pending
-
2021
- 2021-03-17 CY CY20211100224T patent/CY1123957T1/el unknown
-
2022
- 2022-12-21 US US18/069,511 patent/US20230212299A1/en not_active Abandoned
- 2022-12-23 JP JP2022207154A patent/JP2023052067A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533912A5 (2) | ||
| RU2017133273A (ru) | Ингибиторы pd-1 / pd-l1 для лечения рака | |
| CN109153723B (zh) | 抗pd-1抗体与放射的组合治疗癌症 | |
| JP2018070648A5 (2) | ||
| ES2749098T3 (es) | Anticuerpos ANTI-B7-H1 y ANTI-CTLA-4 para tratar el cáncer de pulmón no microcítico | |
| JP2018508512A5 (2) | ||
| RU2018101314A (ru) | Комбинированные способы лечения антагонистами pd-l1 | |
| JP2019519499A5 (2) | ||
| JP2018518454A5 (2) | ||
| JP2015532292A5 (2) | ||
| JP2020508317A5 (2) | ||
| JP2019506403A5 (2) | ||
| HRP20210440T1 (hr) | Kombinirana terapija za rak | |
| RU2019106663A (ru) | Комбинированная терапия рака | |
| JP2017501167A5 (2) | ||
| HRP20220399T1 (hr) | Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost | |
| JP2016520082A5 (2) | ||
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2021513540A5 (2) | ||
| KR102943054B1 (ko) | 면역 체크포인트 저해약 및 폴피리녹스 요법과의 병용에 의한 암 치료 | |
| HRP20171758T1 (hr) | Kombinacija dr5 agonista i anti-pd-1 antagonista i načini primjene | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| RU2018111529A (ru) | Комбинированная терапия для лечения рака | |
| JP2022512851A5 (2) | ||
| RU2019133787A (ru) | Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования |